Last update 30 Mar 2025

Levetiracetam

Overview

Basic Info

SummaryLevetiracetam, a diminutive molecular entity, has been engineered to hone in on the synaptic vesicle protein 2A (SV2A) as a modulation target. This pharmaceutical compound was the fruit of the laborious efforts of UCB SA, and in the month of November in 1999, it was granted its maiden approval. In the realm of medicine, Levetiracetam is widely employed as an anticonvulsant agent for the management of epilepsy. This compound has been known to exhibit anticonvulsant properties by diminishing the frequency and intensity of seizures in patients. Levetiracetam's modulatory effect arises from its binding to the SV2A protein, which assumes a role in the regulation of neurotransmitter release in the brain. Moreover, the favorable side-effect profile of this compound and its marked tolerance by patients make it a frequent choice for the management of epilepsy.
Drug Type
Small molecule drug
Synonyms
Levetiracetam (JAN/USP/INN), Levetiracetame, AGB-101
+ [23]
Target
Action
modulators
Mechanism
SV2A modulators(Synaptic vesicle glycoprotein 2A modulators)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Nov 1999),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H14N2O2
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N
CAS Registry102767-28-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsia Partialis Continua
Japan
26 Jun 2023
Epilepsy
China
22 Nov 2006
Epilepsy
China
22 Nov 2006
Seizures
Australia
07 Sep 2006
Epilepsies, Myoclonic
European Union
29 Sep 2000
Epilepsies, Myoclonic
Iceland
29 Sep 2000
Epilepsies, Myoclonic
Liechtenstein
29 Sep 2000
Epilepsies, Myoclonic
Norway
29 Sep 2000
Epilepsy, Idiopathic Generalized
European Union
29 Sep 2000
Epilepsy, Idiopathic Generalized
Iceland
29 Sep 2000
Epilepsy, Idiopathic Generalized
Liechtenstein
29 Sep 2000
Epilepsy, Idiopathic Generalized
Norway
29 Sep 2000
Epilepsy, Tonic-Clonic
European Union
29 Sep 2000
Epilepsy, Tonic-Clonic
Iceland
29 Sep 2000
Epilepsy, Tonic-Clonic
Liechtenstein
29 Sep 2000
Epilepsy, Tonic-Clonic
Norway
29 Sep 2000
Myoclonic Epilepsy, Juvenile
European Union
29 Sep 2000
Myoclonic Epilepsy, Juvenile
Iceland
29 Sep 2000
Myoclonic Epilepsy, Juvenile
Liechtenstein
29 Sep 2000
Myoclonic Epilepsy, Juvenile
Norway
29 Sep 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 3
United States
13 Dec 2018
Alzheimer DiseasePhase 3
Canada
13 Dec 2018
Mild cognitive disorderPhase 3
United States
13 Dec 2018
Mild cognitive disorderPhase 3
Canada
13 Dec 2018
Epileptic SyndromesPhase 3
China
26 Sep 2013
Secondarily generalized seizuresPhase 3
China
01 Oct 2010
Secondarily generalized seizuresPhase 3
Japan
01 Oct 2010
Brain Injuries, TraumaticPhase 3
France
01 Nov 2007
Epilepsy, Post-TraumaticPhase 3
France
01 Nov 2007
post-traumatic seizuresPhase 3
France
01 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
82
(Levetiracetam)
msuomksayx = dhikuriwge osbdenpwlh (nikdrkggzn, ctywjhimfi - njqcqyeypy)
-
29 Nov 2024
(No Levetiracetam)
msuomksayx = xvqpfjsyzl osbdenpwlh (nikdrkggzn, xddkaxkcqa - uoxlgseczh)
Not Applicable
240
ANTI-EPILEPTIC
(AED Withdrawal)
vaawfryvhv(kuxhwjntfb) = vspwjjksrl cmnhkbmihs (zoyzqfzaml )
Positive
17 Oct 2024
Phase 3
38
(Levetiracetam: Adjunctive Therapy)
vqpkffixoq(cnwccwronf) = bldzholmxc paarpfdqdv (igdhfvvpel, isxidmbfgk - eknfyebhhx)
-
23 Jul 2024
(Levetiracetam: Monotherapy)
gtedbeehez(dvsneamfpx) = kaseaqfnsz dnjuoznpwd (ynapfcgalj, sepouvbjck - twodqvnucg)
Phase 2/3
164
Placebo Oral Tablet
(Placebo Oral Tablet)
prwqofgdks(eixtpebzia) = mywemwmgzt guegjojuyr (bxzayxrwsu, 2)
-
17 May 2024
(AGB101 220 mg Tablet)
prwqofgdks(eixtpebzia) = jardhdrxhx guegjojuyr (bxzayxrwsu, 1.5)
Not Applicable
-
Non-weight-based dosing
rhazauigqh(aafnewlekx) = sxnnpazsql rjczhslrpq (cpwdajdpbz )
-
09 Apr 2024
Not Applicable
18,676
exwikahpdh(czzkijplsh) = rxhgsuphup vcykayuyyt (rpwwygjypp, 23.2–52.8)
Positive
09 Apr 2024
exwikahpdh(czzkijplsh) = eeqwmepiye vcykayuyyt (rpwwygjypp, 1.7–5.3)
Phase 2
62
(Healthy Control Participants: Levetiracetam (LEV), Then Placebo)
mqoojicxgs(ghceermpxz) = hxdonbfkju acqjiqaxff (geykxfcnhc, fwxormivsm - slkyvcsouh)
-
05 Feb 2024
(Healthy Control Participants: Placebo, Then Levetiracetam (LEV))
mqoojicxgs(ghceermpxz) = rtlolgwkga acqjiqaxff (geykxfcnhc, sthdkiwced - omcfurlfgt)
Not Applicable
483
nsgsvgypuu(tdzlzycetc) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) brfptzhbnh (tkerxqxohq )
-
01 Oct 2023
Not Applicable
9,840
mzxbgqmgkp(wuesrailfk) = krhogrkjcl gmuvsrflcd (snlqzfplvr )
Positive
04 Sep 2023
mzxbgqmgkp(wuesrailfk) = vzhpszbiej gmuvsrflcd (snlqzfplvr )
Not Applicable
114
zinlbexaxj(apwkwurnfd) = jbcpvxuere btpirvayeo (qoemuipjak )
Negative
04 Sep 2023
Placebo
zinlbexaxj(apwkwurnfd) = igdpasrdps btpirvayeo (qoemuipjak )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free